JPRN-UMIN000015707招募中2 期
Phase II study of modified FOLFIRINOX as neoadjuvant chemotherapy for borderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancer - Phase II study of modified FOLFIRINOX as neoadjuvant chemotherapy for borderline resectable pancreatic cancer and locally advanced unresectable pancreatic cancer
Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery0 个研究点目标入组 23 人开始时间: 2014年11月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1).Prior radiotherapy or chemotherapy (2).Grade 2 or greater peripheral neuropathy (3).Blood transfusion, administration of blood products, or hematopoietic (e.g., G-CSF) support within 7 days before enrollment (4).Having UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 gene (5).Moderate ascites (6).Intestinal pneumonitis or pulmonary fibrosis (7).Watery stool within 3 days before enrollment (8).Clinically significant heart disease (9).Active infection (HBS,HCV) (10).Uncontrolled diabetes mellitus (11).Serious complications (organ failure, or uncontrolled diabetes mellitus) (12).Serious complications (mental disorder, or central nervous system disorders) (13).Serious drug allergy (14).Active double cancer (15).Pregnancy (16).Treatment with atazanavir sulfate (17).Inappropriate for this study judged by the attending physician
研究者
相似试验
招募中
不适用
A trial of Neoadjuvant modified FOLFIRINOX chemotherapy for resectable pancreatic adenocarcinomaNeoplasmsKCT0004421Yonsei University Health System, Severance Hospital27
已完成
2 期
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic CancerPancreatic AdenocarcinomaNCT02749136Asan Medical Center44
招募中
2 期
eoadjuvant FOLFIRINOX for borderline or locally advanced pancreatic cancerJPRN-jRCT1051190099Toyama Hirochika25
已完成
2 期
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000015376Gifu University Hospital28
已完成
不适用
Phase II study of neoadjuvant FOLFIRINOX or nab-paclitaxel with gemcitabine for borderline resectable pancreatic cancerPancreatic cancerJPRN-UMIN000017718Department of Surgical Oncology, Nagoya University Graduate School of Medicine50